Comment by
sunshine7 on Dec 03, 2015 10:25am
any details or analysis of this report?
Comment by
USNOOZEULOOZE on Dec 03, 2015 10:32am
This post has been removed in accordance with Community Policy
Comment by
pineapple1 on Dec 03, 2015 10:26am
This post has been removed in accordance with Community Policy
Comment by
sunshine7 on Dec 03, 2015 11:40am
I suppose we will get an update to 2016 forecasts in the coming month as CXR gets a chance to read the books and identify unrealized opportunities. IMO earlier forecasts were likely conservative with the unintended consequence of lower target prices (still higher than today's price). Expect surprise to the upside and the analysts like Mackie to revise their recommendations.
Comment by
cg16 on Dec 03, 2015 11:46am
who cares what Mackie Research think they know? Mark Thompson is personally buying shares...
Comment by
Tobuyornot on Dec 03, 2015 10:30am
Certainly seems influential! Anybody able to put some flesh on that report?
Comment by
sunshine7 on Dec 03, 2015 10:41am
In an analyst report shared with investors by Mackie Research on Wednesday morning (Sept 9 2015), Concordia Healthcare Corp (NASDAQ:CXRX) had its target price upped to $81.00. The firm presently has Hold rating on the stock... not very good are they? Now they are a larger, more diversified company and the target is lower? Would like to see their latest report.